Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,041 to 4,060 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays | 53 of 321 230 of 1,310 | -1.0 points -5.3 to 3.8 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations | 91 of 321 433 of 1,310 | -4.7 points -10.0 to 1.0 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Emergency Department Visits | 144 of 321 610 of 1,310 | -1.7 points -7.7 to 4.4 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalization, Emergency Department (ED) Visits, Observation Stays and Deaths | 185 of 321 781 of 1,310 | -2.0 points -8.0 to 3.9 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Deaths Among Participants | 13 of 321 95 of 1,310 | -3.2 points -5.5 to -0.2 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays | 48 of 321 195 of 1,310 | 0.1 points -4.0 to 4.8 | 1,631 | NCT02478359 Walk On! Physical Activity Coaching |
| BuMA Supreme Coronary Stent System (ITT) vs Durable Polymer EES (XIENCE or Promus DES) (ITT): deaths from any cause | 79 of 1,086 41 of 543 | -0.3 points -3.2 to 2.3 | 1,629 | NCT03168776 PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease |
| BuMA Supreme Coronary Stent System (ITT) vs Durable Polymer EES (XIENCE or Promus DES) (ITT): serious adverse events | 210 of 1,086 113 of 543 | -1.5 points -5.7 to 2.6 | 1,629 | NCT03168776 PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease |
| FF/VI 100/25 µg QD vs VI 25 µg QD: Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation | 69 of 806 114 of 814 | -5.4 points -8.5 to -2.4 | 1,620 | NCT02105974 Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100/25 µg QD vs VI 25 µg QD: serious adverse events | 27 of 806 35 of 814 | -0.9 points -2.9 to 1.0 | 1,620 | NCT02105974 Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Aliskiren vs Placebo: serious adverse events | 421 of 808 435 of 810 | -1.6 points -6.4 to 3.3 | 1,618 | NCT00894387 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure |
| All AG200-15 vs Lessina: deaths from any cause | 0 of 1,273 1 of 344 | -0.3 points -1.6 to 0.1 | 1,617 | NCT01181479 Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System |
| All AG200-15 vs Lessina: serious adverse events | 14 of 1,273 4 of 344 | -0.1 points -1.9 to 1.0 | 1,617 | NCT01181479 Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System |
| Aliskiren vs Placebo: Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months | 144 of 808 148 of 807 | -0.5 points -4.3 to 3.2 | 1,615 | NCT00894387 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure |
| Inclisiran vs Placebo: deaths from any cause | 14 of 811 15 of 804 | -0.1 points -1.5 to 1.2 | 1,615 | NCT03400800 Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol |
| Inclisiran vs Placebo: serious adverse events | 181 of 811 181 of 804 | -0.2 points -4.3 to 3.9 | 1,615 | NCT03400800 Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): Number of Children Who Experienced Status Epilepticus | 194 of 822 196 of 792 | -1.1 points -5.3 to 3.0 | 1,614 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Donanemab vs Placebo: Number or Participants With Anti-Donanemab Antibodies | 693 of 793 48 of 821 | 81.5 points 78.5 to 84.1 | 1,614 | NCT04437511 A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) |
| Rotarix Group vs Placebo Group: serious adverse events | 4 of 1,082 7 of 531 | -0.9 points -2.3 to -0.1 | 1,613 | NCT00420316 Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine. |
| Umbilical Cord Milking - Neonates vs Early Cord Clamping - Neonates: Number of Neonates Treated With Normal Saline Bolus in the First 24 Hours of Life | 58 of 823 56 of 790 | -0.0 points -2.6 to 2.5 | 1,613 | NCT03631940 Umbilical Cord Milking in Non-Vigorous Infants |
Code
curl "https://conductscience.org/api/comparisons/v1?page=203"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=203
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02478359-0f64be1d",
"title": "Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Observation Stays",
"summary": "53 of 321 against 230 of 1310; risk difference -1.0 points, 95% interval -5.3 to 3.8; NCT02478359, Walk On! Physical Activity Coaching",
"record": "/library/comparisons/NCT02478359-0f64be1d",
"nct_id": "NCT02478359",
"kind": "outcome",
"participants": 1631,
"risk_difference": {
"value": -0.01046348481605669,
"lower": -0.05294013900048507,
"upper": 0.03820667445678031
},
"group_1": "53 of 321",
"group_2": "230 of 1,310",
"difference": "-1.0 points",
"interval": "-5.3 to 3.8",
"trial_title": "Walk On! Physical Activity Coaching"
},
{
"id": "NCT02478359-0f6d8204",
"title": "Physical Activity Coaching (Walk On!) vs Standard Care: Number of Participants With All-cause Hospitalizations",
"summary": "91 of 321 against 433 of 1310; risk difference -4.7 points, 95% interval -10.0 to 1.0; NCT02478359, Walk On! Physical Activity Coaching",
"record": "/library/comparisons/NCT02478359-0f6d8204",
"nct_id": "NCT02478359",
"kind": "outcome",
"participants": 1631,
"risk_difference": {
"value": -0.047045254571829453,
"lower": -0.10030452249289562,
"upper": 0.01030242820050073
},
"group_1": "91 of 321",
"group_2": "433 of 1,310",
"difference": "-4.7 points",
"interval": "-10.0 to 1.0",
"trial_title": "Walk On! Physical Activity Coaching"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=204",
"request_id": "rX-LcuKBsMbvvcni"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant